| Drug target commons: a community effort to build a consensus knowledge base for drug-target interactions J Tang, B Ravikumar, Z Alam, A Rebane, M Vähä-Koskela, G Peddinti, ... Cell chemical biology 25 (2), 224-229. e2, 2018 | 127 | 2018 |
| Computational-experimental approach to drug-target interaction mapping: a case study on kinase inhibitors A Cichonska, B Ravikumar, E Parri, S Timonen, T Pahikkala, A Airola, ... PLoS computational biology 13 (8), e1005678, 2017 | 106 | 2017 |
| Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling H Kuusanmäki, O Dufva, E Parri, AJ van Adrichem, H Rajala, ... Oncotarget 8 (57), 97516, 2017 | 30 | 2017 |
| Spatial aspects of oncogenic signalling determine the response to combination therapy in slice explants from Kras‐driven lung tumours K Närhi, AS Nagaraj, E Parri, R Turkki, PW van Duijn, A Hemmes, ... The Journal of pathology 245 (1), 101-113, 2018 | 25 | 2018 |
| Identification of novel regulators of STAT3 activity E Parri, H Kuusanmäki, AJ van Adrichem, M Kaustio, K Wennerberg PloS one 15 (3), e0230819, 2020 | 17 | 2020 |
| Chemogenomic analysis of the druggable kinome and its application to repositioning and lead identification studies B Ravikumar, S Timonen, Z Alam, E Parri, K Wennerberg, T Aittokallio Cell chemical biology 26 (11), 1608-1622. e6, 2019 | 16 | 2019 |
| Selective drug combination vulnerabilities in STAT3-and TP53-mutant malignant NK cells E Parri, H Kuusanmäki, D Bulanova, S Mustjoki, K Wennerberg Blood advances 5 (7), 1862-1875, 2021 | 6 | 2021 |
| Targeting STAT3 and kinases in lymphoid malignancies E Parri Helsingin yliopisto, 2021 | | 2021 |
| Spatial aspects of oncogenic signalling determine the response to combination therapy in slice explants from Kras-driven lung tumours K Närhi, AS Nagaraj, E Parri, R Turkki, PW van Duijn, A Hemmes, ... J Pathol 247, 147, 2019 | | 2019 |
| Identifying kinases and phosphatases that regulate STAT3 activity E Parri, H Kuusanmäki, A Adrichem, M Kaustio, L Turunen, K Wennerberg Cancer Research 78 (13_Supplement), 3343-3343, 2018 | | 2018 |
| Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions B Ravikumar, G Repasky, K Wennerberg, T Aittokallio | | 2018 |
| Identifying kinases and phosphatases regulating STAT3 with potential dual anti-cancer effects E Parri, A Van Adrichem, M Kaustio, H Kuusanmäki, L Turunen, ... European Journal of Cancer 1 (69), S73-S74, 2016 | | 2016 |
| 683: Ex vivo modelling of Kras-driven murine non-small cell lung cancer K Närhi, E Parri, A Nagaraj, P Kovanen, R Turkki, A Schoonenberg, ... European Journal of Cancer, S164, 2014 | | 2014 |
